CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum

This publication has 12 references indexed in Scilit:

• In vitro activity of sparfloxacin (AT-4140, CI-978, PD 131501), a new quinolone antimicrobial agent
  Diagnostic Microbiology and Infectious Disease, 1990
• Mycobacterial disease in patients with human immunodeficiency virus infection
  Archives of internal medicine (1960), 1989
• Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis
  Antimicrobial Agents and Chemotherapy, 1989
• In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone
  Antimicrobial Agents and Chemotherapy, 1989
• In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice
  Antimicrobial Agents and Chemotherapy, 1988
• MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs
  Antimicrobial Agents and Chemotherapy, 1988
• Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods
  Antimicrobial Agents and Chemotherapy, 1987
• Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies
  Journal of Antimicrobial Chemotherapy, 1986
• Amikacin, ethambutol, and rifampin for treatment of disseminated Mycobacterium avium-intracellulare infections in patients with acquired immune deficiency syndrome
  Diagnostic Microbiology and Infectious Disease, 1986
• Biological activity of Sch 21420, the 1-N-S-.ALPHA.-hydroxy-.BETA.-aminopropionyl derivative of gentamicin B.
  The Journal of Antibiotics, 1978